Global Next Generation Sequencing Market Size By Type (Targeted Sequencing & Resequencing, Whole Genome Sequencing), By Application (Whole-genome Sequencing, Exome Sequencing), By Region, And Segment...

The Global Next Generation Sequencing (NGS) Market was valued at USD 12.4 billion in 2023 and is projected to reach USD 35.2 billion by 2031, growing at a CAGR of 14.1% during the forecast period (2023–2031). The market’s growth is fueled by increasing demand for precision medicine, advancements in genomics research, and expanding applications of NGS technologies across clinical diagnostics, agriculture, and pharmaceutical development. The reduced cost per genome and improvements in sequencing speed and accuracy are also significantly boosting market adoption globally.

Drivers:

1. Surge in Demand for Precision Medicine:

NGS plays a pivotal role in enabling precision medicine by providing detailed genetic insights, which allow for tailored therapies. The increasing application of NGS in oncology, rare disease diagnostics, and pharmacogenomics is a strong growth catalyst.

2. Technological Advancements:

Innovations such as nanopore sequencing, long-read technologies, and AI-powered data analytics are enhancing NGS accuracy, speed, and affordability, encouraging broader usage across various sectors.

3. Expanding Clinical Applications:

NGS is increasingly being used in infectious disease detection (e.g., COVID-19 variants), reproductive health, and non-invasive prenatal testing (NIPT), driving market penetration in the clinical diagnostics field.

Restraints:

1. High Capital and Operational Costs:

Although per-sample costs have declined, initial investments in NGS instruments and infrastructure remain high, posing a challenge, especially for small- to mid-sized laboratories.

2. Data Interpretation Challenges:

The complexity of NGS data demands robust bioinformatics tools and skilled personnel, which can limit adoption in regions with insufficient genomics expertise or infrastructure.

Opportunity:

1. Rising Adoption in Emerging Markets:

Asia-Pacific and Latin America are witnessing increased government and private investment in genomic research and diagnostics, presenting high-growth opportunities for market players.

2. Integration with AI and Cloud-Based Platforms:

Leveraging AI for variant detection and cloud-based NGS analysis solutions is creating new frontiers for growth by enabling scalability and real-time collaboration.

Market by System Type Insights:

By system type, the Sequencing by Synthesis (SBS) segment dominated the market in 2023 due to its widespread usage in academic and clinical settings for its high throughput, accuracy, and cost efficiency. Meanwhile, Nanopore sequencing is anticipated to grow at the fastest rate due to its potential for real-time and portable genomic analysis.

Market by End-use Insights:

The Academic & Research Institutions segment held the largest share in 2023, driven by continuous investments in genetic research and partnerships with sequencing companies. However, the Clinical Diagnostics segment is expected to witness the highest growth, particularly in oncology, reproductive health, and infectious disease detection.

Market by Regional Insights:

North America led the market in 2023, supported by a robust healthcare infrastructure, leading biotech firms, and strong research funding. The Asia-Pacific region is projected to grow at the fastest rate, driven by genomic initiatives in China and India, expanding biotech sectors, and government-backed genome sequencing projects.

Competitive Scenario:

Key players in the global NGS market include Illumina Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, Pacific Biosciences, BGI Genomics, Agilent Technologies, QIAGEN, PerkinElmer Inc., Roche Holding AG, and 10x Genomics. These companies are focused on strategic collaborations, new product launches, and technological innovation. For example:

In 2024, Illumina introduced a new NovaSeq platform with enhanced scalability and reduced turnaround times.

In 2023, Thermo Fisher expanded its Ion Torrent portfolio, enhancing sequencing speed for clinical workflows.

In 2023, Oxford Nanopore launched a compact sequencer optimized for field applications in infectious disease surveillance.

Scope of Work – Global Next Generation Sequencing Market

Report Metric Details

Market Size (2023) USD 12.4 billion

Projected Market Size (2031) USD 35.2 billion

CAGR (2023–2031) 14.1%

Market Segments By System Type (SBS, Nanopore, SMRT, etc.), By End-use (Academic, Clinical, Pharma/Biotech)

Growth Drivers Precision medicine demand, technological innovation, clinical adoption

Opportunities Emerging markets, AI integration, decentralized sequencing

Key Market Developments:

May 2023: QIAGEN partnered with A*STAR Singapore to develop high-throughput genomic workflows tailored for Southeast Asian populations.

July 2023: BGI Genomics announced a breakthrough in single-cell sequencing to enhance tumor heterogeneity analysis.

February 2024: Pacific Biosciences launched Revio™ System, offering long-read sequencing with lower per-base costs for complex genomes.

FAQs:

1. What is the current market size of the Global Next Generation Sequencing Market?

The market was valued at USD 12.4 billion in 2023.

2. What is the major growth driver of the Global Next Generation Sequencing Market?

The key driver is the increasing demand for precision medicine supported by advancements in sequencing technologies.

3. Which is the largest region during the forecast period in the Global Next Generation Sequencing Market?

North America held the largest share in 2023, but Asia-Pacific is expected to grow at the highest rate through 2031.

4. Which segment accounted for the largest market share in the Global Next Generation Sequencing Market?

The Sequencing by Synthesis (SBS) segment led the market by system type in 2023.

5. Who are the key market players in the Global Next Generation Sequencing Market?

Major players include Illumina Inc., Thermo Fisher Scientific, Oxford Nanopore Technologies, BGI Genomics, and QIAGEN.